Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis

• Published in: Alzheimer's research & therapy Vol. 14; no. 1; pp. 23 - 17
• Main Authors: Chen, Jinghan Jenny, Thiyagarajah, Mathura, Song, Jianmeng, Chen, Clara, Herrmann, Nathan, Gallagher, Damien, Rapoport, Mark J., Black, Sandra E., Ramirez, Joel, Andreazza, Ana C., Oh, Paul, Marzolini, Susan, Graham, Simon J., Lanctôt, Krista L.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.02.2022; BioMed Central; BMC
• Subjects: Alzheimer disease; Alzheimer Disease - psychology; Alzheimer's disease; Animal cognition; Antioxidant; Antioxidants; Bias; Biomarkers; Brain; Brain - metabolism; Cognitive ability; Cognitive Dysfunction - psychology; Cognitive impairment; Complications and side effects; Composition; Dementia; Editorials; Glutathione; Glutathione - metabolism; Health aspects; Human subjects; Humans; Meta-analysis; Neurodegeneration; Oxidative Stress; Plasma; Proteins; Canada; Oxidative stress; Alzheimer disease; Biomarkers; Antioxidant; Cognitive impairment; Glutathione; Meta-analysis
• DOI: 10.1186/s13195-022-00961-5
• ISSN: 1758-9193

Increasing evidence implicates oxidative stress (OS) in Alzheimer disease (AD) and mild cognitive impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) may be important in OS-mediated neurodegeneration, though studies of post-mortem brain GSH changes in AD have been inconclusive. Recent in vivo measurements of the brain and blood GSH may shed light on GSH changes earlier in the disease. To quantitatively review in vivo GSH in AD and MCI compared to healthy controls (HC) using meta-analyses. Studies with in vivo brain or blood GSH levels in MCI or AD with a HC group were identified using MEDLINE, PsychInfo, and Embase (1947-June 2020). Standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated for outcomes using random effects models. Outcome measures included brain GSH (Meshcher-Garwood Point Resolved Spectroscopy (MEGA-PRESS) versus non-MEGA-PRESS) and blood GSH (intracellular versus extracellular) in AD and MCI. The Q statistic and Egger's test were used to assess heterogeneity and risk of publication bias, respectively. For brain GSH, 4 AD (AD=135, HC=223) and 4 MCI (MCI=213, HC=211) studies were included. For blood GSH, 26 AD (AD=1203, HC=1135) and 7 MCI (MCI=434, HC=408) studies were included. Brain GSH overall did not differ in AD or MCI compared to HC; however, the subgroup of studies using MEGA-PRESS reported lower brain GSH in AD (SMD [95%CI] -1.45 [-1.83, -1.06], p<0.001) and MCI (-1.15 [-1.71, -0.59], z=4.0, p<0.001). AD had lower intracellular and extracellular blood GSH overall (-0.87 [-1. 30, -0.44], z=3.96, p<0.001). In a subgroup analysis, intracellular GSH was lower in MCI (-0.66 [-1.11, -0.21], p=0.025). Heterogeneity was observed throughout (I >85%) and not fully accounted by subgroup analysis. Egger's test indicated risk of publication bias. Blood intracellular GSH decrease is seen in MCI, while both intra- and extracellular decreases were seen in AD. Brain GSH is decreased in AD and MCI in subgroup analysis. Potential bias and heterogeneity suggest the need for measurement standardization and additional studies to explore sources of heterogeneity.